Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.